Erich Studerus

List of Publications by Year
in descending order

80 papers	3,189 citations	218677 26 h-index
85 all docs	85 docs citations	85 times ranked

168389 53 g-index
3641 citing authors

#	Article	IF	Citations
1	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
2	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. Scientific Reports, 2022, 12, 6652.	3.3	2
3	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
4	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
5	Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice. Schizophrenia Bulletin, 2021, 47, 284-297.	4.3	101
6	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
7	Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. Journal of Psychopharmacology, 2021, 35, 556-565.	4.0	28
8	Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. Journal of Psychiatric Research, 2021, 136, 428-434.	3.1	17
9	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. Translational Psychiatry, 2021, 11, 312.	4.8	7
10	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
11	Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 539-548.	3.1	9
12	Prospective prediction of suicide attempts in community adolescents and young adults, using regression methods and machine learning. Journal of Affective Disorders, 2020, 265, 570-578.	4.1	34
13	EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients. Frontiers in Psychiatry, 2020, 11, 600606.	2.6	15
14	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6
15	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
16	Traces of Trauma: A Multivariate Pattern Analysis of Childhood Trauma, Brain Structure, and Clinical Phenotypes. Biological Psychiatry, 2020, 88, 829-842.	1.3	35
17	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study. European Psychiatry, 2020, 63, e25.	0.2	14
18	Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders. Schizophrenia Research, 2020, 218, 267-275.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Moderators of treatment efficacy in individualized metacognitive training for psychosis (MCT+). Journal of Behavior Therapy and Experimental Psychiatry, 2020, 68, 101547.	1.2	7
20	Validation of the Bullying Scale for Adults - Results of the PRONIA-study. Journal of Psychiatric Research, 2020, 129, 88-97.	3.1	8
21	Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis. Microbial Biotechnology, 2019, 13, 969-976.	1.7	6
22	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World Journal of Biological Psychiatry, 2019, 20, 545-554.	2.6	37
23	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. Schizophrenia Bulletin, 2019, 46, 252-260.	4.3	13
24	Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. European Psychiatry, 2019, 62, 30-37.	0.2	24
25	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.6	29
26	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning â€" Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
27	No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis. European Journal of Neuroscience, 2019, 50, 3060-3071.	2.6	3
28	Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology, 2019, 29, 539-548.	0.7	7
29	Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. Schizophrenia Research, 2019, 210, 39-47.	2.0	67
30	Individualized prediction of psychosis in subjects with an at-risk mental state. Schizophrenia Research, 2019, 214, 18-23.	2.0	25
31	Gender differences in first selfâ€perceived signs and symptoms in patients with an atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 582-588.	1.7	22
32	Gamma band oscillations in the early phase of psychosis: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 90, 381-399.	6.1	45
33	Sexually dimorphic subcortical brain volumes in emerging psychosis. Schizophrenia Research, 2018, 199, 257-265.	2.0	12
34	The Frankfurt Complaint Questionnaire for selfâ€assessment of basic symptoms in the early detection of psychosisâ€"Factor structure, reliability, and predictive validity. International Journal of Methods in Psychiatric Research, 2018, 27, e1600.	2.1	7
35	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?. European Psychiatry, 2018, 52, 38-44.	0.2	9
36	Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. Microbial Biotechnology, 2018, 12, 66-73.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Outcome of individuals â€œnot at risk of psychosisâ€•and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP). Microbial Biotechnology, 2018, 12, 907-914.	1.7	3
38	Abnormal brain connectivity during error-monitoring in the psychosis high-risk state. Schizophrenia Research, 2018, 193, 261-262.	2.0	1
39	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. Psychology Research and Behavior Management, 2018, Volume 11, 157-168.	2.8	8
40	The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. Psychiatry Research, 2018, 268, 21-27.	3.3	21
41	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. PLoS ONE, 2018, 13, e0196936.	2.5	3
42	Correlations between selfâ€rating and observerâ€rating of psychopathology in atâ€risk mental state and firstâ€episode psychosis patients: influence of disease stage and gender. Microbial Biotechnology, 2017, 11, 461-470.	1.7	11
43	Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychological Medicine, 2017, 47, 1163-1178.	4.5	75
44	Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophrenia Research, 2017, 189, 111-116.	2.0	35
45	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state. Biological Psychology, 2017, 126, 12-18.	2.2	1
46	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state for psychosis and adult attention deficit hyperactivity disorder?. European Psychiatry, 2017, 41, S385-S385.	0.2	0
47	Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis. European Psychiatry, 2017, 41, S198-S198.	0.2	2
48	Stigma in early detection of psychosis: Subjective experiences of those concerned. European Psychiatry, 2017, 41, S387-S387.	0.2	0
49	Duration of untreated psychosis/illness and brain volume changes in early psychosis. Psychiatry Research, 2017, 255, 332-337.	3.3	25
50	Prediction of conversion to psychosis in individuals with an at-risk mental state. Current Opinion in Psychiatry, 2017, 30, 209-219.	6.3	49
51	The role of vulnerability factors in individuals with an at-risk mental state of psychosis. Neuropsychiatrie, 2016, 30, 18-26.	2.5	4
52	High time for a paradigm shift in psychiatry. World Psychiatry, 2016, 15, 131-133.	10.4	6
53	Neurocognition and Motor Functioning in the Prediction of Psychosis. Key Issues in Mental Health, 2016, , 116-132.	0.6	11
54	Neural oscillations in antipsychotic-naÃ¯ve patients with a first psychotic episode. World Journal of Biological Psychiatry, 2016, 17, 296-307.	2.6	12

#	ARTICLE	IF	CITATIONS
55	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naÃ¯ve at-risk patients. World Journal of Biological Psychiatry, 2016, 17, 285-295.	2.6	43
56	Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. CNS Spectrums, 2015, 20, 122-129.	1.2	10
57	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. Schizophrenia Bulletin, 2015, 41, 919-929.	4.3	60
58	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. Schizophrenia Bulletin, 2015, 41, 471-482.	4.3	136
59	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
60	Evidence for an agitatedâ€"aggressive syndrome predating the onset of psychosis. Schizophrenia Research, 2014, 157, 26-32.	2.0	20
61	Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy â€˜Low and High Gatingâ€™ Humans and Relation to Psychometry. Neuropsychopharmacology, 2014, 39, 2485-2496.	5.4	10
62	Gender differences in the psychopathology of emerging psychosis. Israel Journal of Psychiatry, 2014, 51, 85-92.	0.2	4
63	Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology, 2013, 230, 299-308.	3.1	22
64	Help-seeking and pathways to care in the early stages of psychosis. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1033-1043.	3.1	59
65	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Research - Neuroimaging, 2013, 214, 102-108.	1.8	28
66	Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?. Psychiatry Research, 2013, 210, 427-431.	3.3	17
67	2710 â€" Gender differences in the psychopathology of emerging psychosis. European Psychiatry, 2013, 28, 1.	0.2	1
68	Duration of untreated psychosis and cognitive functioning. Schizophrenia Research, 2013, 145, 43-49.	2.0	31
69	Can cognitive deficits facilitate differential diagnosis between atâ€¯risk mental state for psychosis and depressive disorders?. Microbial Biotechnology, 2013, 7, 381-390.	1.7	16
70	Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition. Schizophrenia Bulletin, 2013, 39, 1105-1114.	4.3	64
71	Diurnal Blood Pressure Variations Are Associated with Changes in Distalâ€"Proximal Skin Temperature Gradient. Chronobiology International, 2012, 29, 1273-1283.	2.0	32
72	Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study. Schizophrenia Research, 2012, 142, 217-222.	2.0	52

#	ARTICLE	IF	CITATIONS
73	Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS. Schizophrenia Research, 2012, 136, S300.	2.0	1
74	Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. Biological Psychiatry, 2012, 72, 898-906.	1.3	212
75	Prediction of Psilocybin Response in Healthy Volunteers. PLoS ONE, 2012, 7, e30800.	2.5	245
76	Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology, 2011, 25, 1434-1452.	4.0	346
77	The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Journal of Psychopharmacology, 2011, 25, 1600-1613.	4.0	26
78	Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE, 2010, 5, e12412.	2.5	413
79	Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology, 2009, 23, 923-935.	4.0	40
80	Impaired Prepulse Inhibition and Prepulse-Elicited Reactivity but Intact Reflex Circuit Excitability in Unmedicated Schizophrenia Patients: a Comparison With Healthy Subjects and Medicated Schizophrenia Patients. Schizophrenia Bulletin, 2009, 35, 244-255.	4.3	42